<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03853993</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-QINF-3001</org_study_id>
    <nct_id>NCT03853993</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)</brief_title>
  <official_title>Open Phase I and Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged Over 3 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of quadrivalent
      influenza vaccine in healthy subjects aged over 3 years
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase I&amp; III clinical trial. Phase I is open-labelled, and phase III is
      randomized, double-blind, active-controlled. The purpose of this study is to evaluate the
      safety and immunogenicity of the quadrivalent influenza vaccine (QIV) (experimental vaccine)
      manufactured by Sinovac Biotech Co., Ltd in subjects aged over 3 years. In phase I, 60
      volunteers received single dose QIV (15µg/0.5ml). In phase III, 2320 volunteers were assigned
      to receive single dose QIV (15µg/0.5ml) or two commercial trivalent influenza vaccines (TIVs)
      (15µg/0.5ml) in a ratio of 2:1:1. The commercial TIVs were also manufactured by Sinovac
      Biotech Co., Ltd.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 23, 2018</start_date>
  <completion_date type="Actual">October 8, 2018</completion_date>
  <primary_completion_date type="Actual">August 17, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The phase I clinical trial has single arm, and the phase III clinical trial has 3 parallel arms.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The lower limit of 95% confidence intervals (95%CI) of the ratio of geometric mean titer of hemagglutination inhibition (HI) antibody titer (experimental group/control group)≥2/3.</measure>
    <time_frame>28 days after the injection</time_frame>
    <description>Immunogenicity index, One of the standard to evaluate the experimental vaccine is non-inferior to the control vaccines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The lower limit of 95% CI of the difference of HI antibody seroconversion rate (experimental group-control group)≥-10%</measure>
    <time_frame>28 days after the injection</time_frame>
    <description>Immunogenicity index, Another standard to evaluate the experimental vaccine is non-inferior to the control vaccines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The lower limit of 95%CI of the ratio of GMT(experimental group/control group)＞1.5 .</measure>
    <time_frame>28 days after the injection</time_frame>
    <description>Immunogenicity index, One of the standard to evaluate the experimental vaccine is superior to the control vaccines for specific antigen type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The lower limit of 95% CI of the difference of HI antibody seroconversion rate (experimental group-control group)&gt;10%</measure>
    <time_frame>28 days after the injection</time_frame>
    <description>Immunogenicity index, Another standard to evaluate the experimental vaccine is superior to the control vaccines for specific antigen type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 95% CI lower limit of seroconversion rate of HI antibodies in the subjects aged 3-59 years≥40%</measure>
    <time_frame>28 days after the injection</time_frame>
    <description>Immunogenicity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 95% CI lower limit of seroconversion rate of HI antibodies in the subjects aged over 60 years≥30%</measure>
    <time_frame>28 days after the injection</time_frame>
    <description>Immunogenicity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The seroprotective rate (HI antibody titer≥1:40) in the subjects aged 3-59 years ≥70%</measure>
    <time_frame>28 days after the injection</time_frame>
    <description>Immunogenicity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The seroprotective rate (HI antibody titer≥1:40) in the subjects aged over 60 years ≥60%</measure>
    <time_frame>28 days after the injection</time_frame>
    <description>Immunogenicity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The geometric mean increase (GMI) in the subjects aged 3-59 years &gt;2.5</measure>
    <time_frame>28 days after the injection</time_frame>
    <description>Immunogenicity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The geometric mean increase (GMI) in the subjects aged over 60 years &gt;2.0</measure>
    <time_frame>28 days after the injection</time_frame>
    <description>Immunogenicity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The lower limit of 95%CI of the ratio of GMT(experimental group/control group)≥2/3, in the subjects whose pre-immune HI antibody titer&lt;1:40</measure>
    <time_frame>28 days after the injection</time_frame>
    <description>Immunogenicity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The lower limit of 95% CI of the difference of HI antibody seroconversion rate (experimental group-control group)≥-10%, in the subjects whose pre-immune HI antibody titer&lt;1:40</measure>
    <time_frame>28 days after the injection</time_frame>
    <description>Immunogenicity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of the solicited local and general adverse reactions on day 0-7</measure>
    <time_frame>0-7 days after the injection</time_frame>
    <description>Safety index, The adverse reactions refers to the adverse events which considered related to the vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of the unsolicited adverse events on day 0-28</measure>
    <time_frame>0-28 days after the injection</time_frame>
    <description>Safety Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of the serious adverse events within 6 months after the injection</measure>
    <time_frame>Within 6 months after the injection</time_frame>
    <description>Safety Index</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2380</enrollment>
  <condition>Seasonal Influenza</condition>
  <arm_group>
    <arm_group_label>Experimental group-phase I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadrivalent influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group-phase III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadrivalent influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group-1-phase III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trivalent influenza vaccine (contains B/Victoria strain)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group-2-phase III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trivalent influenza vaccine (contains B/Yamagata strain)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent influenza vaccine</intervention_name>
    <description>Received single dose QIV (15µg/0.5ml)</description>
    <arm_group_label>Experimental group-phase I</arm_group_label>
    <arm_group_label>Experimental group-phase III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent influenza vaccine (contains B/Victoria strain)</intervention_name>
    <description>Received single dose TIV which contains B/Victoria strain (15µg/0.5ml)</description>
    <arm_group_label>Control group-1-phase III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent influenza vaccine (contains B/Yamagata strain)</intervention_name>
    <description>Received single dose TIV which contains B/Yamagata strain (15µg/0.5ml)</description>
    <arm_group_label>Control group-2-phase III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers aged ≥3 years;

          -  Proven legal identity;

          -  Participants or (and) guardians of the participants should be capable of understanding
             the written consent form, and such form should be signed prior to enrolment;

        Exclusion Criteria:

          -  Prior vaccination with influenza vaccine of the current year;

          -  History of influenza within 6 months prior to study entry;

          -  Axillary temperature &gt; 37.0 °C;

          -  History of allergy to any vaccine, or any ingredient of the experimental vaccine,
             especially eggs, egg albumin, etc.;

          -  Serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic
             edema, abdominal pain, etc.;

          -  Severe/uncontrollable nervous system disease (epilepsy, seizures or convulsions) or
             mental illness;

          -  Autoimmune disease or immunodeficiency/immunosuppressive, or any immunosuppressant
             receipt within 6 months prior to the study entry;

          -  History of asthma, thyroidectomy, angioedema, diabetes or malignancy;

          -  No spleen, or functional no spleen, or splenectomy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuemei Hu, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Province Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guanyun Center for Disease Control and Prevention</name>
      <address>
        <city>Lianyungang</city>
        <state>Jiangsu</state>
        <zip>222200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pizhou Center for Disease Control and Prevention</name>
      <address>
        <city>Pizhou</city>
        <state>Jiangsu</state>
        <zip>221300</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza Vaccine</keyword>
  <keyword>Quadrivalent</keyword>
  <keyword>Trivalent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

